scientific payoffs

At present, the main research direction of the company is the 1.1 class of innovative drugs for neurodegenerative diseases. Indications that have been declared for international patents include Alzheimer's disease, Parkinson's disease and glaucoma. Three patent groups have been formed, and experimental data are being collected for five indications to be declared